Enveric Biosciences Expands its Portfolio with Out-Licensing of Psilocin Prodrug Candidate and Sale of Cancer-Related Patent Portfolio
Enveric Biosciences, a biotechnology company specializing in the development of neuroplastogenic small-molecule therapeutics for mental health disorders, has made significant progress in expanding its portfolio. In a recent announcement, Enveric Biosciences revealed the signing of a non-binding term sheet with MindBio Therapeutics to out-license a class of Novel Psilocin Prodrugs (NPP) for the treatment of mental health disorders.
MindBio Therapeutics, a clinical stage biopharma company based in Vancouver, BC, has shown great interest in this novel class of drugs developed by Enveric Biosciences. The non-binding term sheet indicates that both companies have entered into initial discussions to formalize a potential licensing agreement. Under this agreement, Enveric Biosciences would grant MindBio Therapeutics the right to develop, manufacture, and commercialize the NPP drugs for mental health disorders.
Psilocin, the active hallucinogenic compound found in certain psychedelic mushrooms, has shown promise in treating depression, anxiety, and addiction disorders. However, its hallucinogenic effects have limited its usage in clinical settings. Enveric Biosciences aims to address this limitation by developing prodrug candidates that can deliver the therapeutic benefits of psilocin without inducing hallucinations.
MindBio Therapeutics’ interest in acquiring the NPP drugs from Enveric Biosciences suggests a growing recognition of the potential of psychedelic therapies in treating mental health disorders. The clinical stage biopharma company has likely seen the value in Enveric Biosciences’ innovative approach to developing prodrug candidates that minimize or eliminate the hallucinogenic effects of psychedelic-derived compounds.
In another significant move, Enveric Biosciences has agreed to sell one of its cancer-related patent portfolios for an undisclosed amount. This decision reflects the company’s strategic focus on the development of its lead candidates, particularly EB-003. By selling the patent portfolio, Enveric Biosciences can redirect its resources and investments towards advancing its neuroplastogenic small-molecule therapeutics for mental health disorders.
Enveric Biosciences has also highlighted its commitment to research and development by announcing the identification of three novel compounds from its EVM301 Series with the potential to provide a first-in-class approach in addressing difficult-to-treat disorders. These compounds have shown the ability to promote neuroplasticity, a crucial factor in treating mental health disorders, without inducing hallucinogenic effects.
The recent developments by Enveric Biosciences demonstrate the company’s dedication to advancing the field of mental health therapeutics. By expanding its portfolio through licensing agreements, selling non-core assets, and identifying promising compounds, Enveric Biosciences is positioning itself as a leading innovator in the development of neuroplastogenic drugs.
With these significant milestones, Enveric Biosciences is paving the way for the future of mental health treatments. The potential out-licensing of the novel Psilocin Prodrug Candidate to MindBio Therapeutics and the sale of the cancer-related patent portfolio will not only contribute to the company’s growth but also provide hope for millions of individuals struggling with mental health disorders.
Comments